Novabiotics - a leading clinical-stage biotechnology companyABERDEEN 10th NOVEMBER 2020.

NovaBiotics, the anti-infectives and respiratory therapy Biotechnology Company announces the appointment of Dr Malcolm Barratt-Johnson to its Board as Non-Executive Director.

Malcolm is a consultant pharmaceutical physician who has previously served as a Medical Assessor at the UK Department of Health’s Medicines & Healthcare Products Regulatory Agency (MHRA) both within it’s Licensing Division and Clinical Trials Unit.  He has held senior roles within the pharmaceutical and biotechnology industry and worked with the European Commission’s Innovative Medicines Initiative (IMI) to develop and chair several Horizon 2020 projects. Malcolm’s extensive knowledge and expertise in medicinal development, regulation and product launch, further strengthens the NovaBiotics Board as the company moves into an exciting and ambitious phase of development.  Nylexa® is anticipated to enter phase 2 clinical trials for COVID19 in the near future and in 2021 we aim to progress oral Lynovex® into registration studies for infectious pulmonary exacerbations of cystic fibrosis.  In addition, first in human clinical studies are planned for inhaled Lynovex and NP339, NovaBiotics’ antifungal peptide, for invasive fungal disease.

 

ENDS

About NovaBiotics

NovaBiotics Ltd www.novabiotics.co.uk is a clinical-stage biotechnology company focused on the design and development of first-in-class therapies for difficult-to-treat, medically unmet infectious diseases caused by bacteria and fungi and respiratory conditions including cystic fibrosis and COVID-19.  A leading innovator in the anti-infectives space, the Company’s robust technology and business model has been validated through successful development, from concept to late stage clinical development, of its most advanced product candidates.

In addition to the lead  Nylexa® programme for COVID-19 and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, high-value drug candidates including NP339 (Department of Health and Social Care funded programme) for life threatening, drug resistant invasive fungal disease and NP432 for multi-drug resistant bacterial infections.

 

For further information please contact:

 

NovaBiotics:

Dr Deborah O’Neil – CEO

0044 (0)1224 711377

deborah@novabiotics.co.uk

 

Powerscourt:

Jessica Hodgson

+44 (0)7561 424788

jessica.hodgson@powerscourt-group.com